<DOC>
	<DOCNO>NCT02338713</DOCNO>
	<brief_summary>The purpose study demonstrate intestinal absorption calcium novel calcium carbonate-vitamin D3 chewable tablet formulation ( calcium 500 mg vitamin D3 1000 IU ) increase amount calcium excrete urine decrease parathyroid hormone ( PTH ) serum compare Baseline .</brief_summary>
	<brief_title>Effect Calcium 500 mg Vitamin D3 1000 IU Chewable Tablet Intestinal Calcium Absorption</brief_title>
	<detailed_description>The drug test study call Calcichew D3 . Calcichew D3 test ass process body healthy men postmenopausal woman . This study look lab result people take Calcichew D3 . The study enroll approximately 27 patient . All participant receive treatment : â€¢ Calcichew D3 ( calcium 500 mg vitamin D3 1000 IU ) chewable tablet All participant ask take one tablet morning treatment period . This single-centre trial conduct France . The overall time participate study 44 day . Participants make 2 visit clinic , include one 7-day period confinement clinic , contact telephone 14 day last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure include request participant fast laboratory evaluation . 3 . Is healthy adult male female participant . 4 . Female participant postmenopausal ( last menses least 2 year sign informed consent folliclestimulating hormone ( FSH ) confirm postmenopausal status ) . 5 . The participant White . 6 . Is age 45 70 year , inclusive , time inform consent study enrollment . 7 . Weighs least 50 kg body mass index ( BMI ) 18 30 kg/m^2 , inclusive Screening Day 1 . 8 . Is nonsmoker ( abstained smoking least 6 month ) . 1 . Has receive investigational compound within 30 day prior Screening . 2 . Is immediate family member , study site employee , dependant relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 3 . Has uncontrolled , clinically significant neurologic , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , endocrine disease abnormality , may impact ability participant participate potentially confound study result . 4 . Has know hypersensitivity calcium vitamin D3 excipients formulation Calcichew D3 chewable tablet . 5 . Has positive urine drug result drug abuse ( define illicit drug use ) Screening Checkin ( Day 1 ) . 6 . Has history drug abuse ( define illicit drug use ) history alcohol abuse ( define regular consumption 5 unit per day ) within 5 year prior Screening Visit unwilling agree abstain alcohol drug throughout study . One unit equivalent halfpint beer 1 measure spirit 1 glass wine . Ethanol consumption within 72 hour prior Checkin ( Day 1 ) verify alcohol breath test ( Alcotest ) . 7 . Has take exclude medication , supplement , food product time period list Excluded Medications Dietary Products table . 8 . Has current recent ( within 6 month ) gastrointestinal disorder gastrointestinal surgery ( except appendectomy ) would expect influence absorption drug calcium ( ie , history malabsorption , esophageal reflux , peptic ulcer disease , erosive esophagitis , frequent [ per week ] occurrence heartburn , surgical intervention [ eg , cholecystectomy ] ) . 9 . Has history cancer , except basal cell carcinoma remission least 5 year prior Day 1 . 10 . Has positive test result hepatitis B surface antigen ( HBsAg ) , antibody hepatitis C virus ( antiHCV ) , human immunodeficiency virus ( HIV ) antibody Screening . 11 . Has use nicotinecontaining product ( include limit cigarette , pipe , cigar , chew tobacco , nicotine patch nicotine gum ) within 21 day prior Checkin ( Day 1 ) . Cotinine test positive Screening Checkin ( Day 1 ) . 12 . Has poor peripheral venous access . 13 . Has donate lose 450 mL blood volume ( include plasmapheresis ) , transfusion blood product within 30 day prior Day 1 . 14 . Has Screening Checkin ( Day 1 ) abnormal ( clinically significant ) electrocardiogram ( ECG ) . Entry participant abnormal ( clinically significant ) ECG must approve , document signature principal investigator Takeda medical monitor . 15 . Has abnormal Screening Day 1 laboratory value suggest clinically significant underlying disease participant follow laboratory abnormality : alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 2.0 time upper limit normal ( ULN ) . 16 . Is practice vegetarian vegan . 17 . Has creatinine clearance accord Modification Diet Renal Disease equation &lt; 60 mL/min Screening Checkin ( Day 1 ) .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>